Hemophilia B

Rare Disease·MeSH: Hemophilia B

Prevalence

3.0 / 100K

Incidence

4.0 / 100K/yr

17 drugs in development·11 companies·11 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
alprolix	Bioverativ Inc. (BIVV)
hemgenix	uniQure N.V. (QURE)
ixinity	XOMA Royalty Corporation (XOMA)

Phase 3(1)

Drug	Company
fidanacogene elaparvovec	Spark Therapeutics, Inc. (SPARK)

Phase 2(1)

Drug	Company
SerpinPC	Centessa Pharmaceuticals plc (CNTA)

Phase 1(2)

Drug	Company
gene transfer	GH Research PLC (GHRS)
scaav2/8-lp1-hfixco	GH Research PLC (GHRS)

Preclinical(4)

Drug	Company
bivv 002	Bioverativ Inc. (BIVV)
bivv002	Bioverativ Inc. (BIVV)
dtx101	Dimension Therapeutics, Inc. (DMTX)
dtx501	Dimension Therapeutics, Inc. (DMTX)

Unknown(1)

Drug	Company
HEMGENIX	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1/Phase 2(4)

Drug	Company
askbio009	SHIRE PLC (SHPGF)
lnp1265	REGENERON PHARMACEUTICALS, INC. (REGN)
regv131	REGENERON PHARMACEUTICALS, INC. (REGN)
spk-9001	Spark Therapeutics, Inc. (SPARK)

Phase 2/Phase 3(1)

Drug	Company
single dose intravenous injection of bbm-h901	Q BioMed Inc. (QBIO)

BioSniper tracks 17 drugs in development for Hemophilia B across 11 companies.

There are 11 clinical trials targeting Hemophilia B tracked by BioSniper.

The estimated prevalence of Hemophilia B is approximately 3.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.